• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Gold Moves Lower; Microbot Medical Shares Slide

    12/29/23 2:21:47 PM ET
    $CGA
    $FBIO
    $FSR
    $GMM
    Agricultural Chemicals
    Industrials
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CGA alert in real time by email

    U.S. stocks traded lower toward the end of trading, with the Dow Jones index falling more than 50 points on Friday.

    The Dow traded down 0.17% to 37,644.68 while the NASDAQ fell 0.48% to 15,022.70. The S&P 500 also fell, dropping, 0.33% to 4,767.78.

    Check This Out: How To Earn $500 A Month From Annaly Capital Management Stock

     

    Leading and Lagging Sectors

     

    Consumer staples shares rose by 0.01% on Friday.

    In trading on Friday, real estate shares fell by 0.7%.

     

    Top Headline

     

    The Chicago PMI fell to 46.9 in December from 55.8 in the previous month, and compared to market estimates of 51.

     

    Equities Trading UP

     

    Fisker Inc. (NYSE:FSR) shares shot up 15% to $1.7349 after the company provided a December 2023 business update.

    Shares of China Green Agriculture, Inc. (NYSE:CGA) got a boost, surging 60% to $3.0418. On Dec. 27, China Green Agriculture entered into a stock purchase agreement with Zhibiao Pan for the acquisition of all outstanding stock of Lonestar Dream for a total consideration of $49 million.

    Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) shares were also up, gaining 16% to $0.3837. Titan Pharmaceuticals said its Board of Directors has approved a 1-for-20 reverse stock split.

     

    Equities Trading DOWN

     

    Global Mofy Metaverse Limited (NASDAQ:GMM) shares dropped 51% to $5.50.
    Global Mofy Metaverse announced a $10 million follow-on offering.

    Shares of Microbot Medical Inc. (NASDAQ:MBOT) were down 20% to $1.65. Microbot Medical announced exercise of outstanding preferred investment options for $2.73 million in gross proceeds priced at-the-market under Nasdaq rules.

    Fortress Biotech, Inc. (NASDAQ:FBIO) was down, falling 21% to $3.08 as the company announced pricing of $11 million registered direct offering priced at-the-market under Nasdaq rules.

    Also Check This Out: Top 4 Tech And Telecom Stocks That May Fall Off A Cliff In Q4

     

    Commodities

     

    In commodity news, oil traded up 0.3% to $71.96 while gold traded down 0.5% at $2,074.10.

    Silver traded down 0.9% to $24.16 on Friday while copper fell 0.9% to $3.8890.

     

    Euro zone

     

    European shares were higher today. The eurozone’s STOXX 600 gained 0.20%, London’s FTSE 100 rose 0.14% while Spain’s IBEX 35 Index rose 0.16% The German DAX rose 0.30% French CAC 40 rose 0.11% while Italy’s FTSE MIB Index rose 0.07%.

    Spain posted a current account surplus of EUR 3,770 million in October versus a year-ago surplus of EUR 1,228 million. Spain's consumer price inflation eased to 3.1% year-over-year in December from 3.2% in the prior month. The Nationwide House Price Index in the U.K. fell by 1.8% year-over-year in December.

     

    Asia Pacific Markets

     

    Asian markets closed mixed on Friday, with Japan’s Nikkei 225 falling 0.22%, Hong Kong’s Hang Seng Index rising 0.02% and China’s Shanghai Composite Index gaining 0.68%. India’s S&P BSE Sensex, meanwhile, fell 0.23%.

    China reported a current account surplus of $62.8 billion in the third quarter, compared to the preliminary estimate of $62.6 billion.

     

    Economics

     

    The Chicago PMI fell to 46.9 in December from 55.8 in the previous month, and compared to market estimates of 51.

    The total number of active U.S. oil and gas rigs climbed by 2 to 622 rigs this week, Baker Hughes Inc reported.

    Now Read This: Accenture, Lyft And 2 Other Stocks Insiders Are Selling

    Get the next $CGA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CGA
    $FBIO
    $FSR
    $GMM

    CompanyDatePrice TargetRatingAnalyst
    Microbot Medical Inc.
    $MBOT
    2/10/2026$5.00Buy
    B. Riley Securities
    Microbot Medical Inc.
    $MBOT
    12/3/2025$5.50Buy
    Roth Capital
    Fortress Biotech Inc.
    $FBIO
    3/15/2024$10.00Buy
    ROTH MKM
    Fisker Inc.
    $FSR
    3/1/2024Buy → Hold
    R. F. Lafferty
    Fisker Inc.
    $FSR
    3/1/2024Buy → Neutral
    Citigroup
    Fisker Inc.
    $FSR
    1/17/2024$11.00 → $1.00Outperform → Market Perform
    TD Cowen
    Fisker Inc.
    $FSR
    12/4/2023$6.00 → $2.00Outperform → In-line
    Evercore ISI
    Fisker Inc.
    $FSR
    9/26/2023$8.00Buy
    BofA Securities
    More analyst ratings

    $CGA
    $FBIO
    $FSR
    $GMM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Microbot Medical®'s LIBERTY® Endovascular Robotic System Highlighted at a Leading Vascular Disease Management Conference

    International Symposium on Endovascular Therapy (ISET) Convened Key Opinion Leaders to Discuss Advancements and Future Role of Endovascular Robotics LIBERTY® Continues to Gain Commercial Traction and Exposure as Part of Its Limited Market Release (LMR) in the US HINGHAM, Mass., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (NASDAQ:MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, announced that LIBERTY was featured at the International Symposium on Endovascular Therapy (ISET) conference, which took place February 9-12, 2026, in Miami Beach, Florida. The International Symposium on Endovascular Therapy brings together current and emerging

    2/12/26 8:30:00 AM ET
    $MBOT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Global Mofy CEO Haogang Yang, Alongside ByteDance Founder Zhang Yiming and Industry Leaders, Awarded "Top 10 Innovative Economic Figures of the Year" at the 2025 China Economic Summit Forum

    BEIJING, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Global Mofy AI Limited (the "Company" or "Global Mofy") (NASDAQ:GMM), a generative AI-driven technology solutions provider engaged in virtual content production and the development of 3D digital assets for use in the broader digital content industry, today announced that its Founder and Chief Executive Officer, Mr. Haogang Yang, was recognized as one of the "Top 10 Innovative Economic Figures of the Year" at the 2025 China Economic Summit Forum. Mr. Yang was honored alongside other award recipients, including Mr. Yiming Zhang, founder of ByteDance, the parent company of TikTok, as well as leaders from China's healthcare, logistics, enterprise sof

    2/11/26 8:53:16 AM ET
    $GMM
    Computer Software: Programming Data Processing
    Technology

    Mofy VFX × Tencent Video: Breakout Urban Comedy Series "No Pain No Gain" Premieres, with Global Mofy Delivering End-to-End VFX Production Powered by AI-Native Workflow

    BEIJING, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Global Mofy AI Limited (the "Company" or "Global Mofy") (NASDAQ:GMM), a generative AI-driven technology solutions provider engaged in virtual content production and the development of 3D digital assets for use in the broader digital content industry, today announced that its visual effects ("VFX") brand, Mofy VFX, provided end-to-end VFX production services for the urban workplace comedy series "No Pain No Gain", produced by Xinli TV and Yuewen Film & TV, which premiered on Tencent Video on January 31, 2026. As of the date of this release, the series' Tencent Video in-platform "heat index"—an internal popularity metric—has surpassed 24,000, with p

    2/9/26 8:45:00 AM ET
    $GMM
    Computer Software: Programming Data Processing
    Technology

    $CGA
    $FBIO
    $FSR
    $GMM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    PRESIDENT, CEO & CHAIRMAN Rosenwald Lindsay A Md bought $1,404,581 worth of shares (763,359 units at $1.84), increasing direct ownership by 26% to 3,657,264 units (SEC Form 4)

    4 - Fortress Biotech, Inc. (0001429260) (Issuer)

    9/25/24 4:45:04 PM ET
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President, CEO & Chairman Rosenwald Lindsay A Md bought $37,418 worth of SERIES A CUMULATIVE PERPETUAL PREFERRED STOCK (5,000 units at $7.48), increasing direct ownership by 4% to 127,500 units (SEC Form 4)

    4 - Fortress Biotech, Inc. (0001429260) (Issuer)

    7/15/24 4:05:14 PM ET
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Jin David bought $3,750 worth of SERIES A CUMULATIVE PERPETUAL PREFERRED STOCK (500 units at $7.50) (SEC Form 4)

    4 - Fortress Biotech, Inc. (0001429260) (Issuer)

    7/12/24 8:42:21 AM ET
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CGA
    $FBIO
    $FSR
    $GMM
    SEC Filings

    View All

    Microbot Medical Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Microbot Medical Inc. (0000883975) (Filer)

    2/12/26 8:30:51 AM ET
    $MBOT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 424B3 filed by Global Mofy AI Limited

    424B3 - Global Mofy AI Ltd (0001913749) (Filer)

    2/11/26 4:11:26 PM ET
    $GMM
    Computer Software: Programming Data Processing
    Technology

    SEC Form EFFECT filed by Global Mofy AI Limited

    EFFECT - Global Mofy AI Ltd (0001913749) (Filer)

    2/10/26 12:15:19 AM ET
    $GMM
    Computer Software: Programming Data Processing
    Technology

    $CGA
    $FBIO
    $FSR
    $GMM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Klein Dov was granted 27,322 shares, increasing direct ownership by 27% to 130,105 units (SEC Form 4)

    4 - Fortress Biotech, Inc. (0001429260) (Issuer)

    1/5/26 4:30:44 PM ET
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Harvey Jimmie was granted 27,322 shares, increasing direct ownership by 23% to 146,704 units (SEC Form 4)

    4 - Fortress Biotech, Inc. (0001429260) (Issuer)

    1/5/26 4:30:43 PM ET
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Lorenz Kevin was granted 27,322 shares, increasing direct ownership by 37% to 101,009 units (SEC Form 4)

    4 - Fortress Biotech, Inc. (0001429260) (Issuer)

    1/5/26 4:30:37 PM ET
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CGA
    $FBIO
    $FSR
    $GMM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    B. Riley Securities initiated coverage on Microbot Medical with a new price target

    B. Riley Securities initiated coverage of Microbot Medical with a rating of Buy and set a new price target of $5.00

    2/10/26 8:01:31 AM ET
    $MBOT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Roth Capital initiated coverage on Microbot Medical with a new price target

    Roth Capital initiated coverage of Microbot Medical with a rating of Buy and set a new price target of $5.50

    12/3/25 8:38:40 AM ET
    $MBOT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    ROTH MKM resumed coverage on Fortress Biotech with a new price target

    ROTH MKM resumed coverage of Fortress Biotech with a rating of Buy and set a new price target of $10.00

    3/15/24 7:18:10 AM ET
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CGA
    $FBIO
    $FSR
    $GMM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Fortress Biotech Inc.

    SC 13G - Fortress Biotech, Inc. (0001429260) (Subject)

    10/25/24 10:15:19 AM ET
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Fortress Biotech Inc.

    SC 13D/A - Fortress Biotech, Inc. (0001429260) (Subject)

    9/25/24 4:45:18 PM ET
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Titan Pharmaceuticals Inc.

    SC 13D/A - TITAN PHARMACEUTICALS INC (0000910267) (Subject)

    8/21/24 8:32:38 AM ET
    $TTNP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CGA
    $FBIO
    $FSR
    $GMM
    Leadership Updates

    Live Leadership Updates

    View All

    DIH Appoints Scott R. Burell to DIH Holding US, Inc. Board of Directors

    NORWELL, Mass., Aug. 08, 2025 (GLOBE NEWSWIRE) -- DIH Holding US, Inc. ("DIH")(NASDAQ:DHAI), a global provider of advanced robotic devices used in rehabilitation, which incorporate visual stimulation in an interactive manner to enable clinical research and intensive functional rehabilitation and training in patients with walking impairments, reduced balance and/or impaired arm and hand functions, today announced the appointment of Scott R. Burell to its Board of Directors. Scott R. Burell is a seasoned healthcare finance executive with over two decades of experience leading public life sciences companies through complex transactions and growth phases. Currently serving as Chief Financia

    8/8/25 8:00:00 AM ET
    $DHAI
    $MBOT
    Medical/Dental Instruments
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Microbot Medical® Expands Commercial Leadership with Appointment of Christina Bailey as VP of Sales

    HINGHAM, Mass., July 22, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (NASDAQ:MBOT), developer of the innovative LIBERTY® Endovascular Robotic System, announced the appointment of Christina Bailey as its new Vice President of Sales. A two-time U.S. Olympian with 20 years of medical device sales experience, Ms. Bailey has successfully led commercial teams to achieve sales goals.  She will report directly to Harel Gadot, the Company's CEO, President and Chairman. Ms. Bailey has held a variety of sales leadership roles. She has worked with notable companies like Boston Scientific, Abbott, Stryker and Intuitive Surgical that have equipped her with the insights necessary to drive growth and

    7/22/25 8:30:00 AM ET
    $MBOT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Journey Medical to Join Russell 2000® and Russell 3000® Indexes

    SCOTTSDALE, Ariz., June 24, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical" or the "Company", "we", or "our"), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Administration ("FDA") approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that the Company will join the small-cap Russell 2000® Index and the broad-market Russell 3000® Index, effective after the close of U.S. equity markets on June 27, 2025, as a result of their 2025 annual Russell Index reconstitution. "We are very pleased to be included in the Russell 2000® and Russell 3000

    6/24/25 8:30:29 AM ET
    $DERM
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CGA
    $FBIO
    $FSR
    $GMM
    Financials

    Live finance-specific insights

    View All

    Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Approval of ZYCUBO® (copper histidinate), the First and Only Approved Treatment for Menkes Disease in the United States

    Rare Pediatric Disease Priority Review Voucher (PRV) granted by FDA at approval to be transferred from Sentynl Therapeutics to Cyprium Cyprium eligible to receive tiered royalties and up to $129 million in aggregate development and sales milestones from Sentynl Therapeutics MIAMI, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ:FBIO) ("Fortress") and its majority-owned subsidiary, Cyprium Therapeutics, Inc. ("Cyprium"), today announced that the U.S. Food and Drug Administration ("FDA") has approved ZYCUBO® (copper histidinate, formerly known as CUTX-101) for the treatment of Menkes disease in pediatric patients. In December 2023, Sentynl Therapeutics, Inc. ("Sentynl"),

    1/13/26 7:45:00 AM ET
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Fortress Biotech and Cyprium Therapeutics Announce FDA Acceptance of CUTX-101 NDA Resubmission

    MIAMI, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ:FBIO) ("Fortress") and its majority-owned subsidiary, Cyprium Therapeutics, Inc. ("Cyprium"), today announced that the U.S. Food and Drug Administration ("FDA") has accepted the resubmission of the New Drug Application ("NDA") for CUTX-101 (copper histidinate), intended to treat Menkes disease in pediatric patients. The resubmission has been accepted as a Class 1 resubmission and as a result, the new Prescription Drug User Fee Act (PDUFA) target action date for the NDA is January 14, 2026. In December 2023, Sentynl Therapeutics, Inc. ("Sentynl"), a U.S.-based biopharmaceutical company wholly owned by Zydus Lifescienc

    12/15/25 8:00:00 AM ET
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Journey Medical Corporation Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights

    Third quarter 2025 net revenues were $17.6 million Emrosi™ total prescriptions increased 146% over the second quarter of 2025 Emrosi net revenues were $4.9 million Company to hold conference call today at 4:30 p.m. ET to discuss the financial results and provide a business update SCOTTSDALE, Ariz., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical," "the Company," "we" or "our"), a commercial-stage pharmaceutical company primarily focused on selling and marketing FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced financial results and recent corporate highlights for the third quar

    11/12/25 4:01:00 PM ET
    $DERM
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care